Agata I. Schramm-Luc
Agata is an internist and rheumatologist. She is a lecturer (research/teaching) in the Department of Internal and Rural Medicine of the Jagiellonian University in Krakow, Poland.
In her work she combines practice in the Rheumatology Outpatient Clinics with research in the Translational Medicine Laboratory. Her main scientific interest is the role of the immune system in hypertension in rheumatoid arthritis and inflammatory spondyloarthropathies.
Agata is an active member of the Young Rheumatologists’ Sub-Committee of Polish Society of Rheumatology, member of the Polish Society of Internal Medicine and a member of the EMEUNET Peer-Mentoring Sub-Committee.
| Oral 0775| Sunday, 26.10.25 10:30 Plenary Session: Plenary I Presenting author: A. Phothisane (USA) Title: Increased Circulating Microbial Small RNA tDR-1 is Associated with Decreased Progression to Future Clinical Rheumatoid Arthritis In High Risk Individuals and Reduces In Vitro Type 1 Interferon Response Gene Expression  This study demonstrates bacteria-originated tRNA-derived RNA as a biomarker associated with decreased future development of rheumatoid arthritis among at-risk individuals. Suggested mechanism is downregulation of interferon signaling. |
| Poster 0092| Sunday, 26.10.25 10:30 Poster Session A: Rheumatoid Arthritis – Etiology and Pathogenesis Poster Presenting author: M. Fazli (USA) Title: SynovAI: A Revolutionary AI Framework for Enhanced Detection and Differentiation of Rheumatoid Arthritis, Osteoarthritis, and Spondyloarthritis via Advanced Ultrasound Imaging This proof-of-concept work presents an innovative approach using artificial intelligence framework to augment musculoskeletal ultrasound interpretation. |
| Poster 0479| Sunday, 26.10.25 10:30 Poster Session A: Rheumatoid Arthritis – Treatment Poster I Presenting author: A. Khanfar (USA) Title: Risk of Arrhythmias Following IL-6 Inhibitor Use; A Pharmacosurvellience Study of FDA Adverse Event Reporting System (FAERS) This pharmacovigilance analysis reports increased prevalence of specific arrhythmias in patients receiving IL-6 inhibitors. |
| Oral 1675| Monday, 27.10.25 13:15 Abstract Session: Rheumatoid Arthritis – Treatment I: Preventative and Novel Treatments Presenting author: G. Valenzuela (USA) Title: Neuroimmune modulation in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors (TNFi) This subgroup analysis from the RESET-RA study presents clinical effectiveness of neuroimmune modulation by implantation of cervical vagus nerve stimulator in rheumatoid arthritis patients with inadequate response or intolerance to TNF inhibitors. |
| Oral 1724| Tuesday, 28.10.25 8:30 Plenary Session: Plenary III Presenting author: M. Lesturgie-Talarek (France) Title: Pathogenic role of Mucosal-Associated Invariant T cells in Rheumatoid Arthritis. This study, performed in in vitro and in vivo models, reveals reduction in Mucosal-Associated Invariant T cells in blood and accumulation in synovial fluid in rheumatoid arthritis. Furthermore, it describes their phenotypic, functional, and transcriptomic alterations. |
| Oral 2640| Wednesday, 29.10.25 9:45 Abstract Session: Rheumatoid Arthritis – Treatment II: Phenotyping and Personalization Presenting author: S. Fukui (USA) Title: Effectiveness of Biological and Target-Synthetic Treatment in Patients with Rheumatoid Arthritis and Kidney Dysfunction: A Large Prospective Registry Study This large prospective registry study shows that rheumatoid arthritis patients with reduced eGFR are less likely to achieve remission on biologic and targeted synthetic DMARDs than patients with non-reduced eGFR. |
| Oral 2641| Wednesday, 29.10.25 10:00 Abstract Session: Rheumatoid Arthritis – Treatment II: Phenotyping and Personalization Presenting author: R. Grieshaber-Bouyer (Germany) Title: Cizutamig, a BCMA T-cell engager: preclinical to clinical translation of design optimization for the treatment of autoimmune diseases This study demonstrates safety profile and clinical activity of T-cell engager designed to reduce cytokine release while maintaining killing of B cell maturation antigen-expressing cells. |
| Oral 2682| Wednesday, 29.10.25 11:45 Abstract Session: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes III: Long Live (Comorbidity and Outcomes) Presenting author: A. Medeiros-Ribeiro (Brazil) Title: Methotrexate use and higher age impair humoral response against the recombinant herpes zoster vaccine (RZV) in Rheumatoid Arthritis: a prospective, randomized, placebo-controlled trial This trial demonstrates safety of recombinant vaccine against herpes zoster in rheumatoid arthritis patients together with identifying methotrexate usage and older age as factors impairing humoral response. |